HQL offers a 14.2% dividend yield and diverse exposure to healthcare and life science companies. Since abrdn's acquisition in 2023, HQL has delivered a total return of 25.5%, though its price ...
Tekla Life Sciences Investors invests primarily in biotechnology stocks, and 10-12 large-cap biotech stocks (50% of total holdings) sets the trend and price direction for this fund. Poor price growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback